肝细胞癌的血管正常化与免疫治疗 #br#

肝细胞癌（HCC）是常见的恶性肿瘤之一，大部分患者确诊时往往为晚期，失去手术的机会，此时药物治疗 成为重要的治疗手段，包括化疗、靶向、免疫、中药及内分泌治疗等。免疫治疗是一种新兴的癌症治疗方式，然而异 常的肿瘤血管形成免疫抑制的肿瘤微环境，限制了免疫治疗的发展。抗血管生成治疗能够抑制肿瘤血管生长，修复 异常的肿瘤血管系统，成为改善免疫治疗的新策略。本文就HCC的血管正常化与免疫治疗的关系及两者的联合治 疗进行综述。

Vascular normalization and immunotherapy in hepatocellular carcinoma #br#

Hepatocellular carcinoma (HCC) is one of the most common malignancies. Most patients are diagnosed late and lose the opportunity for surgery at the late stage. At this time, medication becomes an important treatment, including chemotherapy, targeting, immunity, traditional Chinese medicine and endocrine therapy. Immunotherapy is a new way of cancer treatment, but the abnormal tumor angiogenesis forms an immunosuppressive tumor microenvironment, which limits the development of immunotherapy. Antiangiogenic therapy has become a new strategy to improve immunotherapy by inhibiting tumor vascular growth and repairing abnormal tumor vascular system. This article reviews the relationship between blood vessel normalization and immunotherapy in HCC and the combination of them.